[HTML][HTML] Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor in vitro

K Shionoya, M Yamasaki, S Iwanami, Y Ito… - Frontiers in …, 2021 - frontiersin.org
Coronavirus disease 2019 (COVID-19) has caused serious public health, social, and
economic damage worldwide and effective drugs that prevent or cure COVID-19 are urgently …

Multidrug treatment with nelfinavir and cepharanthine against COVID-19

H Ohashi, K Watashi, W Saso, K Shionoya, S Iwanami… - BioRxiv, 2020 - biorxiv.org
Antiviral treatments targeting the emerging coronavirus disease 2019 (COVID-19) are
urgently required. We screened a panel of already-approved drugs in a cell culture model of …

[PDF][PDF] Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment

H Ohashi, K Watashi, W Saso, K Shionoya, S Iwanami… - Iscience, 2021 - cell.com
Antiviral treatments targeting the coronavirus disease 2019 are urgently required. We
screened a panel of already approved drugs in a cell culture model of severe acute respiratory …

[HTML][HTML] An ACAT inhibitor suppresses SARS-CoV-2 replication and boosts antiviral T cell activity

…, J Newman, N Thakur, K Shionoya… - PLoS …, 2023 - journals.plos.org
The severity of disease following infection with SARS-CoV-2 is determined by viral replication
kinetics and host immunity, with early T cell responses and/or suppression of viraemia …

Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA. 1 and BA. 2

…, T Hishiki, D Akazawa, KS Kim, J Woo, K Shionoya… - Antiviral Research, 2022 - Elsevier
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant BA.2
has spread in many countries, replacing the earlier Omicron subvariant BA.1 and other …

Potential anti-mpox virus activity of atovaquone, mefloquine, and molnupiravir, and their potential use as treatments

…, ES Park, M Kataoka, K Shionoya… - The Journal of …, 2023 - academic.oup.com
Background Mpox virus (MPXV) is a zoonotic orthopoxvirus and caused an outbreak in 2022.
Although tecovirimat and brincidofovir are approved as anti-smallpox drugs, their effects in …

Identification of IMP Dehydrogenase as a Potential Target for Anti-Mpox Virus Agents

…, ES Park, M Kataoka, J Mifune, K Shionoya… - Microbiology …, 2023 - Am Soc Microbiol
Mpox virus (formerly monkeypox virus [MPXV]) is a neglected zoonotic pathogen that
caused a worldwide outbreak in May 2022. Given the lack of an established therapy, the …

Potential anti-monkeypox virus activity of atovaquone, mefloquine, and molnupiravir, and their potential use as treatments

…, KS Kim, YD Jeong, ES Park, M Kataoka, K Shionoya… - BioRxiv, 2022 - biorxiv.org
Monkeypox virus (MPXV) is a zoonotic orthopoxvirus that causes smallpox-like symptoms in
humans and caused an outbreak in May 2022 that led the WHO to declare global health …

[HTML][HTML] Should a viral genome stay in the host cell or leave? A quantitative dynamics study of how hepatitis C virus deals with this dilemma

…, K Kitagawa, H Ohashi, Y Asai, K Shionoya… - PLoS …, 2020 - journals.plos.org
Virus proliferation involves gene replication inside infected cells and transmission to new
target cells. Once positive-strand RNA virus has infected a cell, the viral genome serves as a …

Anti-severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) potency of Mefloquine as an entry inhibitor in vitro

K Shionoya, M Yamasaki, S Iwanami, Y Ito, S Fukushi… - bioRxiv, 2020 - biorxiv.org
Coronavirus disease 2019 (COVID-19) has caused serious public health, social, and
economic damage worldwide and effective drugs that prevent or cure COVID-19 are urgently …